Literature DB >> 22460068

Effect of epinephrine on platelet-activating factor-stimulated human vascular smooth muscle cells.

Peter Vadas1, Boris Perelman.   

Abstract

BACKGROUND: Animal and human data show that platelet-activating factor (PAF) mediates the life-threatening manifestations of anaphylaxis. Although administration of epinephrine is the mainstay of therapy of acute anaphylaxis, the interaction between epinephrine and PAF has not been studied. In particular, the effect of the timing of epinephrine administration on the action of PAF has not been examined.
OBJECTIVE: Using human vascular smooth muscle cells (HVSMCs), we examined the effect of timing of epinephrine addition on the action of PAF.
METHODS: The effect of epinephrine on PAF-mediated prostaglandin E(2) (PGE(2)) release from human aortic smooth muscle cells was examined. Epinephrine was added at various times before and after PAF stimulation.
RESULTS: HVSMCs stimulated with PAF released PGE(2) in a concentration- and time-dependent manner. Whereas preincubation of HVSMCs with epinephrine before the addition of PAF suppressed PGE(2) release, treatment with epinephrine after PAF stimulation was less effective with time after PAF stimulation. PGE(2) release was suppressed by means of preincubation with 8-bromo-cyclic AMP and forskolin.
CONCLUSIONS: PAF induced PGE(2) release from HVSMCs in a concentration- and time-dependent manner, and early addition of epinephrine was essential for the control of PAF-induced PGE(2) release. Epinephrine was most effective when administered before stimulation with PAF but was progressively less effective with time after PAF stimulation.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460068     DOI: 10.1016/j.jaci.2012.02.027

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  International consensus on (ICON) anaphylaxis.

Authors:  F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm
Journal:  World Allergy Organ J       Date:  2014-05-30       Impact factor: 4.084

2.  Intraoperative Hypotension in a Patient with Antithrombin Deficiency, Bilateral Pulmonary Emboli, and Cefazolin Allergy.

Authors:  Aaron R Muncey; Nasrin N Aldawoodi; Ahish Chitneni; Jamie P Hoffman; Allan R Escher
Journal:  Cureus       Date:  2021-03-02

Review 3.  Workup and Clinical Assessment for Allergen Immunotherapy Candidates.

Authors:  Constantinos Pitsios; Konstantinos Petalas; Anastasia Dimitriou; Konstantinos Parperis; Kyriaki Gerasimidou; Caterina Chliva
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

4.  Downregulation of angiogenesis factors, VEGF and PDGF, after rapid IgE desensitization and oral immunotherapy in children with food allergy.

Authors:  Paloma Poza-Guedes; Yvelise Barrios; Victoria Fuentes; Andres Franco; Inmaculada Sánchez-Machín; Elena Alonso; Ruperto González Pérez; Sonsoles Infante; Lydia Zapatero; Víctor Matheu
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

5.  Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.

Authors:  Boris Perelman; Areej Adil; Peter Vadas
Journal:  Allergy Asthma Clin Immunol       Date:  2014-04-28       Impact factor: 3.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.